Darifenacin (hydrobromide) (Standard)

• UNSPSC Description:

  Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3].

• Target Antigen:

  Akt; mAChR; p38 MAPK

• Type:

  Reference Standards

• Related Pathways:

  GPCR/G Protein;MAPK/ERK Pathway;Neuronal Signaling;PI3K/Akt/mTOR

• Field of Research:

  Cancer; Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/darifenacin-hydrobromide-standard.html

• Smiles:

  O=C(C(C1=CC=CC=C1)([C@@H]2CCN(CCC3=CC4=C(OCC4)C=C3)C2)C5=CC=CC=C5)N.Br

• Molecular Weight:

  507.46

• References & Citations:

  [1]Hegde SS, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol, 1997, 120(8), 1409-1418.|[2]Miller DW, et al. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers. Neurourol Urodyn, 2011, 30(8), 1633-1638.|[3]Iijima K, et al. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol, 2007, 52(3), 842-847.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Launched

• CAS Number:

  133099-07-7